Latest / Stock Movers / Drax Gains, Zalando Slides, Bayer Rises
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio, news. The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market,
- 0:13Speaker 1: harnessing the power of Bloomberg data.
- 0:16Speaker 2: Thank you very much, Stephen. Well, let's take a look
- 0:18Speaker 2: at some of the stocks on the move today in Europe.
- 0:20Speaker 2: I'm Tiwa Adebayo with Stephen Carroll, and we are joined
- 0:24Speaker 2: by Bloomberg reporter Josh Gorm Warner. Josh, let's start with Drax.
- 0:29Speaker 2: We're seeing shares rise this morning.
- 0:31Speaker 3: Yeah, the company is known for operating the UK's largest
- 0:35Speaker 3: power station up in North Yorkshire. And it's rising today
- 0:38Speaker 3: after Brookfield Asset Management and the Qatar Investment Authority agreed
- 0:41Speaker 3: to invest £ 2. 5 billion in a data centre project alongside
- 0:46Speaker 3: the company. Those two are hoping to tap into an
- 0:49Speaker 3: existing grid connection at the power station in order to
- 0:52Speaker 3: get the initial phase up and running pretty quickly, hopefully
- 0:54Speaker 3: by early 2028. And ultimately, this might be the first
- 0:59Speaker 3: proposed data center to bypass the UK's lengthy grid connection queue. So,
- 1:04Speaker 3: we've seen Drax in the past rely on government subsidies
- 1:07Speaker 3: for its biomass generation, but that support is starting to decline.
- 1:11Speaker 3: And so, Drax, like other utility firms, is now looking
- 1:14Speaker 3: at new revenue streams and data centers seem to be
- 1:16Speaker 3: like a good place to start. Analysts are awaiting more
- 1:19Speaker 3: details on the deal, but they like the fact that
- 1:21Speaker 3: it's got credible partners and it shows that it's got
- 1:24Speaker 3: new opportunities to chase So, shares are having their best
- 1:27Speaker 3: day in over a year, up as much as 9%.
- 1:29Speaker 3: And they're trading at their highest level since May.
- 1:33Speaker 1: Okay. So, that's in terms of Drax. Let's go to
- 1:36Speaker 1: the online fashion retailer Zalando next. What's the news from them? Yeah.
- 1:40Speaker 3: The stock is sliding this morning after reporting third quarter results.
- 1:44Speaker 3: They were broadly in line with expectations. And some analysts
- 1:48Speaker 3: at Metzeler highlighted that investors might be booking some profits
- 1:51Speaker 3: considering the stock was up about 20% in the month
- 1:54Speaker 3: leading up to today's print. So, earnings were as expected.
- 1:58Speaker 3: But some analysts did flag that the gross margin was
- 2:00Speaker 3: a bit softer than hoped. Jeffrey said that was a
- 2:03Speaker 3: surprise considering some of the positive messaging from the company.
- 2:06Speaker 3: And it's also raising questions about the sustainability of its
- 2:10Speaker 3: growth in gross merchandise volume. You know, growth with margin
- 2:14Speaker 3: dilution is often quite a hard sell. So, concerns around
- 2:17Speaker 3: the margin, a lack of sort of really any good
- 2:19Speaker 3: news today is snapping the recent strong run in the shares.
- 2:23Speaker 3: They were down as much as 8% in early trade.
- 2:25Speaker 3: They've pared back a bit, but they are pulling back
- 2:27Speaker 3: from a three-month high nonetheless.
- 2:29Speaker 2: I know we've got a story that we put out
- 2:30Speaker 2: in advance of those results from Zalando on the terminal
- 2:33Speaker 2: saying that they might be a victim of sneaker weakness. So,
- 2:37Speaker 2: we could demand for sportswear brands leading to an inventory build-up.
- 2:41Speaker 2: And it does remind me of something that our opinion columnist,
- 2:44Speaker 2: Andrew Felstead, wrote recently about people wanting to wear more
- 2:46Speaker 2: formal shoes to the office. So, perhaps that's having a
- 2:49Speaker 2: bearing in terms of their share price this morning. But lastly,
- 2:52Speaker 2: let's move to a drug maker buyer raising its annual
- 2:56Speaker 2: profit outlook. Yeah.
- 2:58Speaker 3: So, the company beat expectations and upped its outlook. That
- 3:02Speaker 3: improvement is being driven by increased demand for some of
- 3:06Speaker 3: its newer drugs. That includes one that treats prostate cancer
- 3:10Speaker 3: and another that provides kidney therapy. So, the demand for
- 3:13Speaker 3: these new drugs like Nubeca and Corendia actually prompted the CEO,
- 3:17Speaker 3: Bill Anderson, to say that the pharma division has finally
- 3:20Speaker 3: reached a turning point in terms of growth. And that's
- 3:24Speaker 3: important because, you know, the demand for these newer drugs
- 3:26Speaker 3: is helping to offset the generic competition that faces some
- 3:30Speaker 3: of its other medicines, such as a blood thinner drug
- 3:32Speaker 3: and its eye medicine. And also, other parts of the
- 3:35Speaker 3: business are also struggling. We saw a big stumping earnings
- 3:38Speaker 3: at its crop science division. So, a much needed boost
- 3:40Speaker 3: from newer drugs there. Analysts said that, you know, the
- 3:44Speaker 3: lengthy overhang from the ongoing Roundup litigation, which is a
- 3:48Speaker 3: weed killer, has also eased compared to a couple of
- 3:51Speaker 3: years ago. We've seen sentiment around that really boost the
- 3:54Speaker 3: stock recently. And buyer up over 5% today and at
- 3:58Speaker 3: a four-month high.
- 4:01Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:05Speaker 1: us throughout the day for the latest roundup of companies
- 4:07Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 4:12Speaker 1: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:16Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:19Speaker 1: Business app.